PG Diploma not equal to PG degree for assistant professor promotions: Himachal HC

Shimla: In a recent judgment, the Himachal Pradesh High Court has ruled that a postgraduate diploma cannot be considered equivalent to a postgraduate degree for promotion to the post of Assistant Professor under the Himachal Pradesh Medical Education Services Rules, 1999.

After going through the provisions of the rules, the HC bench comprising Justice Vivek Singh & Justice Sushil Kukreja observed, “Bare reading of the provisions includes that prescribed essential qualification is Post Graduation Degree or its equivalent qualification with condition that such candidate must possesses 3 years teaching experience after doing Post Graduation. The word ‘after doing Post Graduation’ relates to the minimum essential qualification, i.e. Post Graduation Degree in concerned speciality or its equivalent. In case, there would have been intention to include teaching experience after doing Post Graduation Diploma, then it would have been mentioned specifically in the Rules that teaching experience can be gained after doing either Post Graduation Decree or Diploma. There is no reference of Post Graduation Diploma in the essential qualification, therefore, meaning of words ‘after doing Post Graduation’ has to be construed as “after doing Post Graduation Degree”.”

“In absence of reference of “Diploma” in the essential qualification at any place, the Post Graduation Diploma cannot be imported for interpreting the word ‘after doing Post Graduation’ as Post Graduation Degree or Diploma or to say that these words include Post Graduation Diploma also in addition to Post Graduation Degree referred in earlier part of Rules providing essential qualification as Post Graduation Degree,” noted the HC bench.

These observations were made by the Court while considering the plea filed by the petitioner, who completed his MBBS in 2006 and after working for a few years, got his MD from Dr. Rajendra Prasad Government Medical College, Tanda in 2024. Thereafter, the petitioner joined as a Medical Officer in Chamba Medical College.

Filing the plea, the petitioner argued that as per the Himachal Pradesh Medical Education Service Rules, 1999, 50% of Assistant Professor Posts are to be filled through promotion of in-service doctors. According to the petitioner, his three years of teaching experience as a Senior Resident, after completing the PG medical diploma, should be counted towards eligibility.

However, the petitioner claimed that the Departmental Promotion Committee ignored his claim and recommended another candidate for the promotion instead.

While considering the plea, the HC bench, after examining the Service Rules of 1999, noted that the minimum qualification for an Assistant Professor is a Postgraduate degree, and since there is no mention of a diploma in the Rules, it cannot be read into them.

At this outset, the Court remarked that the 1999 rule demanded three years of teaching experience after a postgraduate degree, and the teaching experience of the petitioner as a Senior Resident, gained after a diploma, but before his MD Degree, did not satisfy the requirement.

The bench pointed out that in Civil Appeal No. 4415 of 2011 (Manish Sharma’s case) the question considered by the Apex Court was that “whether the PostGraduate Diploma possessed by the appellant was equivalent to the prescribed qualification of a Post-Graduate Degree in Anesthesiology’ and it was observed by the Court that said question was required to be decided by the competent authority in terms of Rules and the appeal was disposed of by the Apex Court directing the respondent-competent Authority to take a decision in terms of applicable Rules.

“The Apex Court had not decided the issue on merit, but had left it open to be decided by Competent Authority. There is nothing on record to say that Competent Authority had decided that Post Graduate Degree and Post Graduate Diploma are one and the same thing,” the HC bench observed at this outset.

Accordingly, the HC bench upheld the decision of the departmental promotion committee, which had declared the petitioner ineligible. The Court noted,

“In view of above observations, we are of the considered opinion that respondents as well as Departmental Promotion Committee had rightly arrived at conclusion that at the time of conducting the meeting of DPC, petitioner was not eligible to be appointed as Assistant Professor Anesthesiology for want of essential qualification provided under the relevant Rules.”

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/himachal-pradesh-hc-promotion-303220.pdf

Also Read: Himachal HC slams govt for ‘ulterior motive’ in retiring professor at 65, orders reinstatement

Powered by WPeMatico

Zydus Lifesciences Secures CDSCO Panel Approval for Usnoflast Capsule Interaction Study

New Delhi: The Subject Expert Committee (SEC) on Investigational New Drugs under CDSCO has recommended approval for Zydus Lifesciences Limited to carry out a Phase I Drug-Drug Interaction (DDI) study of its investigational molecule Usnoflast (ZYIL 1) in capsule strengths of 25 mg, 50 mg, and 75 mg.

The decision came at the committee’s meeting on September 4, 2025, held at CDSCO headquarters in New Delhi.

The firm presented its Phase II clinical study report (ZYIL1.23.003, Version 01, dated October 24, 2024) along with the Drug-Drug Interaction Phase I study protocol (C1B05514, Version 01, dated March 12, 2025). These submissions were made in response to earlier recommendations of the 06th/25th SEC (IND) meeting held on July 8, 2025

Usnoflast (ZYIL 1) is an oral small molecule currently under development for potential use in inflammatory and autoimmune disorders. These conditions often require long-term treatment, making it vital to establish how new drugs interact with commonly prescribed therapies. Drug-drug interaction studies are an essential part of the clinical process, helping determine whether a new treatment can be safely combined with existing medications without reducing effectiveness or increasing side effects.

.After detailed evaluation, the committee noted the Phase II outcomes and recommended that the Phase I study be conducted as per the proposed protocol.

Zydus Lifesciences is a drug major known for its innovation-driven approach. The company’s R&D efforts cover a wide spectrum of therapeutic areas, including oncology, metabolic disorders, infectious diseases, and immunology. Its ongoing focus on developing novel molecules has positioned Zydus as a significant contributor to clinical research both in India and globally.

Also Read: CDSCO Panel Rejects Theon Pharma’s Proposal for Empagliflozin, Linagliptin, Metformin FDC

Powered by WPeMatico

Jharkhand HC directs Govt to frame HIV guidelines for prison inmates

Ranchi: The Jharkhand High Court has directed the State Government to formulate and implement comprehensive guidelines for HIV testing and treatment for prison inmates, in accordance with the Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017.

The Court’s intervention follows concerns raised over inadequate healthcare facilities for prisoners, particularly regarding HIV.

Also Read:4 Tamil Nadu Private medical colleges partner to offer free STD treatment

According to the TOI, during the hearing of a criminal appeal for bail filed by a convict, a division bench of Justice Sujit Narayan Prasad and Justice Sanjay Prasad was informed that the petitioner tested positive for HIV. The court then summoned the officers concerned by the government to further investigate the matter.

The Division Bench of Justice Sujit Narayan Prasad and Justice Sanjay Prasad observed, “Section 49 confers power upon the State Government to make out Rules for carrying out the provisions of this Act,” reports the Verdictum.

The Appellant was represented by Advocate Shailesh Kr. Singh, while the Respondent was represented by Additional Advocate General Sachin Kumar.

The Court observed that Section 5 of the Act prohibits the performance of any HIV test on an individual, in accordance with the non-obstante clause, except as provided by the provisions of this Act. Additionally, Section 13 mandates that both the Central Government and each State Government, as applicable, must take all necessary and appropriate measures to prevent the spread of HIV or AIDS, in alignment with the prescribed guidelines.

During the hearing, the court took note of a joint submission from the Additional Chief Secretary of Health and the Principal Secretary of the Department of Home, Jail & Disaster Management. The submission assured the court that the Jharkhand State Government would take necessary steps in consultation with the AIDS Control Society to formulate specific guidelines for HIV testing and treatment in prisons.

Also Read: WHO Issues Updated Guideline on HIV Service Delivery

According to the Verdictum, the Court additionally observed, “The Additional Chief Secretary, Health, although has stated that in terms of the instruction issued by the National AIDS Control Organisation, Ministry of Health & Family Welfare, Government of India, dated 12th January, 2024, the State of Jharkhand is also making an endeavour to get the prisoners tested to put a check upon the spread of HIV… If such instruction has already been issued, its effective implementation is to be ensured by the authorities concerned”. 

The Jharkhand High Court has adjourned the matter until November 17, 2025, giving the state government time to develop and implement the guidelines.

Powered by WPeMatico

Radiation exposure from imaging in children increased risk of hematologic cancer: NEJM

A new study published in The New England Journal of Medicine showed a link between radiation exposure from medical imaging and a tiny but considerable elevated risk of hematologic cancer in children and adolescents.

Although medical imaging, especially computed tomography (CT), it exposes them to ionizing radiation. There is evidence that cumulative radiation exposure raises the risk of cancer, particularly hematologic malignancies. In pediatric treatment, it is essential to comprehend this relationship to strike a balance between long-term safety and diagnostic advantages. Thus, this study was evaluated the risk of radiation-induced hematologic malignancy in children and adolescents based on medical imaging.

This research tracked a retrospective cohort of 3,724,623 infants born in 6 U.S. health care systems and Ontario, Canada, between 1996 and 2016 until the earliest of the following events: death, cessation of health care coverage, age 21, diagnosis of cancer or benign tumor, or December 31, 2017. Medical imaging radiation exposures to active bone marrow were measured. Continuous-time hazards models were used to evaluate associations between cumulative radiation exposure (as opposed to no exposure) and hematologic malignancies with a 6-month lag.

A total of 2961 hematologic malignancies were identified throughout the course of 35,715,325 person-years of follow-up, mostly lymphoid cancers (2349 [79.3%]), myeloid tumors or acute leukemia (460 [15.5%]), and histiocytic or dendritic cell cancers (129 [4.4%]). Children exposed to at least 1 mGy had an overall mean (±SD) exposure of 14.0±23.1 mGy, whereas children with hematologic cancer had an exposure of 24.5±36.4 mGy.

With a relative risk of 1.41 (95% CI), 1.11 to 1.78 for 1 to less than 5 mGy, 1.82 (95% CI, 1.33 to 2.43) for 15 to less than 20 mGy, and 3.59 (95% CI, 2.22 to 5.44) for 50 to less than 100 mGy, the risk of cancer increased with cumulative dosage.

A higher risk of all hematologic malignancies and the majority of tumor subtypes was linked to the cumulative radiation exposure to bone marrow. Among children exposed to at least 30 mGy (mean, 57 mGy), the elevated cumulative incidence of hematologic malignancies by age 21 was 25.6 per 10,000.

According to our estimates, radiation exposure from medical imaging may have contributed to 10.1% (95% CI, 5.8 to 14.2) of hematologic malignancies in our cohort, with larger risks associated with higher-dose medical imaging procedures like CT. Overall, a dose-dependent increase in the incidence of hematologic malignancies was linked to cumulative radiation exposure from medical imaging throughout infancy. 

Source:

Smith-Bindman, R., Alber, S. A., Kwan, M. L., Pequeno, P., Bolch, W. E., Bowles, E. J. A., Greenlee, R. T., Stout, N. K., Weinmann, S., Moy, L. M., Stewart, C., Francisco, M., Kofler, C., Duncan, J. R., Ducore, J., Mahendra, M., Pole, J. D., & Miglioretti, D. L. (2025). Medical imaging and pediatric and adolescent hematologic cancer risk. The New England Journal of Medicine,. https://doi.org/10.1056/nejmoa2502098

Powered by WPeMatico

Unichem Labs Slapped Rs 1.77 Crore NPPA Notice for Alleged Overpricing of 3 Drugs

New Delhi: Unichem Laboratories Limited has received three demand notices from the National Pharmaceutical Pricing Authority (NPPA), alleging overcharging for three of its drugs over various periods between 2013 and 2018. The notices, issued under para 15 of the Drug Price Control Order (DPCO), 2013, carry a total penalty of Rs 1.77 crore.

The demand notices, dated 29th September 2025 and received by the company on 3rd October 2025, cite alleged overpricing for the following periods: July 2013 to November 2018, February 2016 to November 2018 and January 2016 to November 2018.

It is noteworthy that Unichem had sold its domestic formulation business in December 2017, which partially overlaps with the alleged period of violation.

Despite the notices, the company has assessed that the penalties are not expected to have any material impact on its financials, operations, or other business activities. Unichem Laboratories is reportedly evaluating legal options to address the NPPA’s notices.

Also Read: NPPA Revises Ceiling Prices of Essential Drugs Including Riboflavin, Dialysis Solutions, Others; Details

The disclosure was made under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, to the BSE and NSE, where the company’s shares are listed under the script codes 506690 (BSE) and UNICHEMLAB (NSE).

Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories, confirmed that the company will act in accordance with the applicable legal framework.

Also Read: NPPA Extends Price Cap on Knee Implants Until November 15, 2025

Powered by WPeMatico

Sresan Pharma’s Coldrif Syrup Banned After 48.6% Toxic Diethylene Glycol Detected

Chennai: The Ministry of Health and Family Welfare has confirmed that Coldrif Cough Syrup, manufactured by Sresan Pharma at its Kanchipuram, Tamil Nadu facility, contains diethylene glycol (DEG) beyond permissible limits. Fresh laboratory analysis has declared the drug Not of Standard Quality (NSQ), detecting a toxic 48.6% concentration of DEG, a substance linked to the deaths of at least nine children in Madhya Pradesh’s Chhindwara district and two children in Rajasthan.

Diethylene glycol (DEG) is an organic compound found in household products but also as a counterfeit solvent in medicines. DEG poisonings are characterized by acute kidney injury (AKI).Diethylene glycol (DEG) is nephrotoxic, potentially resulting in high morbidity and mortality. Its main nephrotoxic by-product is diglycolic acid (DGA).

State authorities in Tamil Nadu conducted tests on samples collected directly from Sresan Pharma’s Kanchipuram manufacturing site and confirmed DEG contamination. Earlier, the Madhya Pradesh Food and Drug Administration (MPFDA) had analysed three of 13 collected samples, which were reportedly free of contamination.

“As part of the ongoing investigation, it is further informed that a total of six samples were collected by CDSCO, which were tested, and all 6 were found to be free of DEG/EG. Simultaneously, MPFDA had informed that out of 13 samples collected by their team, 3 were analysed, which were found to be free of DEG/EG. At the request of the MP Govt, Tamil Nadu FDA had taken samples of Coldrif Cough Syrup from the manufacturing premises of M/S Sresan Pharma in Kanchipuram, Tamil Nadu. The results of testing these samples were shared with us late yesterday evening, 3rd October 2025. The samples are found to contain DEG beyond the permissible limit,” the Ministry was quoted as saying by ET.

In response, the Tamil Nadu government has banned the sale of Coldrif syrup across the state from October 1 and ordered withdrawal of existing stocks. Production at Sresan Pharma’s Kanchipuram facility has been suspended pending further investigation. The syrup had been distributed in Madhya Pradesh, Rajasthan, and Puducherry, reports PTI.

Also Read: Cough Syrup Row: Rajasthan Practitioners Shift to Levocloperastine, Ambroxol Amid Dextromethorphan Concerns

As per ANI report, the Office of the Controller Food and Drugs Administration, Madhya Pradesh, issued a formal order stating:

“As you are aware that deaths of children have been reported in Chhindwara District of Madhya Pradesh. In this regard, the Office of the Director of Drugs Control, Tamil Nadu, Chennai has informed that ‘Coldrif Syrup’ has been declared NSQ (Not of Standard Quality) with respect to samples, as it contains Diethylene Glycol (48.6% w/v), a poisonous substance which may render the contents injurious to health. It is directed to stop further sale and distribution of ‘Coldrif Syrup’ immediately.”

The order also directed the halt of sale and distribution of all other products manufactured by Sresan Pharma in the larger public interest.

Authorities have launched risk-based inspections across six states where 19 drug samples were collected. A multidisciplinary panel including experts from NIV, ICMR-NEERI, CDSCO, and AIIMS Nagpur is investigating the samples and other related factors to determine the cause of the deaths, reports ET.

In Madhya Pradesh, authorities have restricted the sale of both Coldrif and Nesto DS syrups. Officials confirmed that 594 bottles had been distributed to three local distributors, with some consignments still pending test results. Families reported that affected children’s initial cold and cough symptoms escalated into severe kidney complications.

So far, nine child fatalities have been reported in Madhya Pradesh, while Rajasthan has recorded two infant deaths.

Meanwhile, the Union Health Ministry has issued an advisory to all states and Union Territories instructing that cough and cold syrups should not be prescribed to children under two years of age. The Directorate General of Health Services (DGHS) has reiterated that cough and cold medicines should not be prescribed or dispensed to children below two years of age. Such drugs are generally discouraged for those under five, and for older children, their use must be strictly based on clinical evaluation, with careful dosing, close supervision, short treatment duration, and avoidance of multiple drug combinations. The advisory also urged that the public be made more aware of the importance of adhering to prescriptions.

Also Read: Cough Syrup crisis: Rajasthan govt suspends drug controller, halts distribution of Kaysons Pharma medicines

Powered by WPeMatico

Medical Negligence? Patient alleges toes amputated without consent at Alappuzha MCH

Alappuzha: In a case of alleged medical negligence, a 58-year-old woman from Kuthiyathodu has accused the doctors in the surgery department of Alappuzha Medical College Hospital of amputating two toes on her right foot without her or her family’s consent. 

While the woman and her family claimed that they were not informed about the amputation and came to know only after the surgery, the Alappuzha Medical College Hospital authorities denied the allegations. They stated that her two toes had fallen off on their own due to her severe diabetic condition and that this was noticed while doctors were removing the dressing to check the wound.

Also read- Medical Negligence? HIMS doctors accused of operating on wrong leg

The incident came to light after the woman was admitted to the hospital’s surgical ward on September 27, following the injury caused by a nail that had pierced through her foot. She underwent surgery on September 29, but according to her family, the procedure was done without informing them about the nature of the operation.

Her family stated that they came to know about the amputation only the next day, when senior doctors visited her for a follow-up check-up, as she was complaining of pain, as per a Mathrubhumi news report. 

Following the discovery, her son approached the hospital superintendent and the district medical officer and subsequently filed a complaint. In response, the hospital superintendent formed a three-member expert committee to investigate the matter.

However, hospital authorities have denied the allegations of negligence. Superintendent Dr A Harikumar said the patient had a severe diabetic foot infection with poor blood circulation, and her condition was critical. 

“Her feet were completely infected, with limited blood flow. While removing the dressing to inspect the wound, her toes fell off. She complained that the matter was not communicated to her properly. An emergency panel was formed, and its report has been submitted. Further action will be based on that,” he told Onmanorama.

Also read- Infant dies after alleged medical negligence at Capital Hospital; protests erupt

Powered by WPeMatico

51 Lakh people in India are at risk of contracting Chikungunya in the Long Term: Study

India is projected to face the most significant long-term impact of chikungunya, with an estimated 51 lakh people at risk annually, according to a global modelling study published in BMJ Global Health. Brazil and Indonesia follow as the second and third most affected countries, with India and Brazil together accounting for 48% of the global healthcare and individual burden. Researchers from the London School of Hygiene and Tropical Medicine highlight chronic health effects as the major concern, with about half of those infected potentially suffering long-term disabilities.

Globally, over 1.4 crore people could be at risk yearly, predominantly children under 10 and adults over 80. Chikungunya is transmitted by Aedes mosquitoes, causing fever, severe joint pain, and in many cases, prolonged disability. With no specific treatments, two vaccines are approved in some countries, including the US. The study emphasizes urgent public health preparedness and targeting vulnerable populations for vaccination to mitigate this growing threat.

REFERENCE: Kang H, Lim A, Auzenbergs M, Clark A, Colón-González FJ, Salje H, et al. Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study. BMJ Global Health. 2025;10:e018598. https://doi.org/10.1136/bmjgh-2024-018598

Powered by WPeMatico

15 Indian psychiatrists, doctors, scientists listed in Stanford 2025 List of World’s Top 2% Scientists

New Delhi: A total of 15 psychiatrists from India’s leading health and medical institutions have been recognised in the Stanford list of the world’s top 2% scientists. The prestigious database, curated by Professor John P.A. Ioannidis of Stanford University in collaboration with the Elsevier Data Repository, acknowledges their pioneering research, clinical excellence, and sustained impact in the field of psychiatry.

Stanford University’s database of top-cited scientists for the year 2025 provides standardised information on citations, h-index, co-authorship-adjusted h-index, citations to papers in different authorship positions, and a composite indicator (c-score). The selection is based on the top 100,000 scientists by c-score (with and without self-citations) or a 2% or above percentile rank in the sub-field.

Below are the details of Indian psychiatrists featured in Stanford University’s list for 2025:

1. Dr Chittaranjan Andrade:

Dr Chittaranjan Andrade, a Senior Professor in the Department of Clinical Psychopharmacology and Neurotoxicology at the National Institute of Mental Health and Neuro Sciences (NIMHANS) in Bengaluru, has over four decades of experience in clinical psychopharmacology, research, and education. His academic achievements began early, with 25 prizes in pre-collegiate education, 4 prizes during college, and 9 gold medals in medical school, including the Best Outgoing Student Award from his university. He stood 4th in Karnataka during his undergraduate education and topped the university in his postgraduate examinations.

Over his prolific career, Dr Andrade has authored 784 publications, with more than 216,000 reads and 14,600 citations. His primary research interests include ketamine, psychopharmacology, electroconvulsive therapy, statistics, and research methodology. In the 2024 Stanford University global database, he was ranked among the top 0.1% of scientists across 174 fields. This year, in the 2025 Stanford list, he has achieved a rank of 881 based on the composite score, excluding self-citations. By the end of 2024, Dr Chittaranjan Andrade’s h-index, excluding self-citations, stands at 16.

He plays an active role in advancing psychiatric education. He serves as Field Editor (Clinical Therapeutics) for Bipolar Disorders and sits on the editorial boards of several leading journals, including the Journal of Clinical Psychiatry, Journal of ECT, Brain Stimulation, and the Indian Journal of Psychiatry, among others. He has guided numerous postgraduate theses and is widely recognized as a dedicated mentor and educator.

In addition, he runs two major academic initiatives: Synergy Times, a thrice-weekly global e-newsletter published since 2001, and e-Journal Club India, launched in 2016 to support postgraduate psychiatry students and faculty in research methodology and academic publishing. Beyond psychiatry, Dr Andrade is a published children’s author, with three books to his name. He is also a columnist and freelance journalist, having written over 800 articles across a range of topics.

2. Dr. Debanjan Banerjee:

Dr. Debanjan Banerjee is a distinguished Consultant Geriatric Psychiatrist at Apollo Hospitals, Kolkata. His work focuses on the psychosocial impact of the COVID-19 pandemic, the psychology of misinformation, media reporting of suicides, and the marginalization of ageing populations.

His journey into psychiatry began with his MBBS from Calcutta National Medical College, followed by a gold medal for his academic excellence. Building on this foundation, he completed his M.D. in Psychiatry from NIMHANS before embarking on a post-doctoral fellowship in Geriatric Psychiatry. His passion for mental health in aging populations led him to specialise in old-age mental health, an area that remains underexplored but is crucial as the global population ages rapidly.

With 139 publications, over 56,578 reads, and 5,668 citations, Dr Banerjee has significantly contributed to the academic literature in social psychiatry and geriatrics. His research interests are wide-ranging, with a particular emphasis on social constructivist approaches, including Interpretative Phenomenological Analysis (IPA), Cognitive Grounded Theory (CGT), and Focus Group Discussions (FGD).

According to the data, he is recognized in the Stanford 2% Scientists list, holding a rank of 20,414 based on the composite score excluding self-citations, and 23,538  when all citations are included. By the end of 2024, his h-index, excluding self-citations, stands at 11, with a total of 485 citations for the year, also excluding self-citations.

He plays an active role in various community programs focused on mental health awareness, stigma reduction, and the training of general physicians. Additionally, he conducts research in social psychology. Apart from these contributions, he serves as the editor for two local magazines based in Kolkata.

3.  Dr Sandeep Grover:

Dr Sandeep Grover, a distinguished Professor of Psychiatry, is currently serving in the Department of Psychiatry at the prestigious Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh.

Dr Grover’s dedication to psychiatric education is evident through his role as a Professor at PGIMER, where he mentors postgraduate students and conducts research.

With over 1,132 publications, Dr. Grover’s research has made significant contributions to the global understanding of psychiatric disorders, their treatment, and their social impact.

He holds a rank of 22,329 in the list based on the composite score excluding self-citations. By the end of 2024, his h-index, excluding self-citations, stands at 13, with a total of 1579 citations for the year, also excluding self-citations.

4. Dr. Lakshmi Sagar Vijayakumar:

As the founder of SNEHA (Suicide Prevention Program) in Chennai, Dr. Vijayakumar has impacted countless lives through her work in the prevention of suicide, offering support to individuals in crisis, and raising awareness about mental health challenges.

She also serves as the Head of the Department of Psychiatry at Voluntary Health Services in Adyar, Chennai. An active member of the World Health Organization’s International Network for Suicide Research and Prevention, Dr. Vijayakumar is an Honorary Associate Professor at the University of Melbourne, Australia.

Previously, she served as the Vice President of the International Association for Suicide Prevention (IASP) for four years and received the prestigious Ringel Service Award for her contributions. She has been honoured with the Honorary Fellowship of the Royal College of Psychiatrists (FRCPsych) in the UK and the Fellowship of the Royal College of Physicians of Edinburgh (FRCP EDIN) for her extensive work on suicide prevention.

Her pioneering work has gained global recognition. In 2014, Dr. Vijayakumar was a co-editor of the WHO’s report titled “Preventing Suicide — A Global Imperative.”

She has published extensively in peer-reviewed journals, authored numerous book chapters, and edited two books on the subject. In India, she has received several prestigious awards, including the ‘For The Sake of Honour’ Award, Bharathi Virudu, and the Women Doctor of the Year Award. She has been a tireless advocate for the decriminalization of suicide, the establishment of media guidelines for reporting suicide, and the development of a national suicide prevention strategy for India.

According to the Stanford 2% Scientist list, he holds a rank of 23,506. By the end of 2024, his h-index, excluding self-citations, stands at 18.

5. Dr Ravi Philip Rajkumar:

Dr Ravi Philip Rajkumar, currently working as a Professor of Psychiatry at JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research) in Pondicherry, is renowned for his work in the areas of psychopharmacology, neuropsychiatry, and psychosomatic disorders.

Dr. Rajkumar holds an M.B.B.S. and M.D. in Psychiatry, qualifications that have laid a solid foundation for his career in both medicine and psychiatry. As a professor, he plays an active role in educating the next generation of psychiatrists and mental health professionals.

He has been recognized as one of the top 2% scientists worldwide, according to Stanford University’s list for 2025, where he holds the rank of 29,405.

6. Dr Sujita Kumar Kar

Dr. Sujita Kumar Kar is an academic researcher currently based at King George’s Medical University (KGMU) in Lucknow, where he contributes significantly to the field of psychiatry and neuropsychiatry.

Dr. Kar completed his MBBS from MKCG Medical College, Berhampur, in 2004 and went on to pursue advanced research and clinical work in psychiatry. He has authored 361 research papers and has been cited 584 times for his work, making notable contributions in areas such as mood disorders, psychosis, and biological psychiatry. His research interests primarily focus on non-invasive brain stimulation (neuromodulation).

In 2025, he is recognized as one of the top 2% of scientists globally according to Stanford’s list, with a rank of 45,404. By the end of 2024, his h-index, excluding self-citations, stands at 13, with a total of 40,546 citations for the year, also excluding self-citations.

7. Dr. Kuruthukulangara Sebastian

Dr. Kuruthukulangara Sebastian Jacob is an esteemed academic and researcher, currently affiliated with the University of Melbourne, Melbourne, Australia.

Dr. Jacob has an extensive publication record with 8,665 citations drawn from 6,820 documents. He has authored 255 research papers and boasts a notable h-index of 52. Additionally, he has one preprint and has collaborated with 421 co-authors over the course of his career.

Notably, he is ranked in Stanford University’s list of top 2% scientists worldwide for 2025, with an impressive rank of 52,559.

His research interests span a variety of topics, including DSM-IV, the sleep-waking cycle, overactive bladder, urolithiasis, and chronic obstructive pulmonary disease (COPD). He is also focused on evidence-based medicine, radiology, and community mental health. Additionally, his work includes exploring neuroticism, the International Classification of Diseases (ICD-10), and the role of hydrocortisone in various medical conditions.

8. Dr Om Prakash Singh:

Dr. Om Prakash Singh, a distinguished psychiatrist, currently serves as a professor at Midnapore Medical College. Previously, he held prestigious positions, including Professor of Psychiatry at IPGMER and SSKM Hospital, as well as Assistant Professor at Burdwan Medical College, where he later became Professor and Head of the Psychiatry Department.

Dr. Singh’s academic journey began with his studies at Scottish Church College, Calcutta, followed by his medical training at Lady Hardinge Medical College and later at Burdwan Medical College and Hospital. With his vast experience and expertise, Dr. Singh has contributed significantly to both clinical psychiatry and medical education.

He has been recognised as one of the top 2% scientists across the world, as per Stanford University’s list of 2025. According to the data, Dr. Om Prakash Singh holds a rank of 62,399 in the list. By the end of 2024, his h-index, excluding self-citations, stands at 8.

9. Dr. Santosh Kumar Chaturvedi

Dr. Santosh Kumar Chaturvedi is a renowned figure in the field of psychiatry and behavioural sciences, holding the prestigious position of Former Dean, Behavioural Sciences and Professor of Psychiatry at the National Institute of Mental Health & Neurosciences (NIMHANS) in Bangalore.

Dr. Chaturvedi’s academic journey began at Maulana Azad Medical College, where he earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree. His passion for understanding the human mind and mental health led him to pursue further specialization in psychiatry, earning a Doctor of Medicine (MD) in Psychiatry from the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh between 1979 and 1982.

He is a member of both the International Psycho-Oncology Society and the Indian Association of Palliative Care. He has also served as a member of the Board of Directors for the International Psycho-Oncology Society.

In addition to his academic and clinical roles, Dr. Singh regularly conducts workshops on Communication Skills in Oncology and Palliative Care settings and trains trainers to teach these essential skills. His areas of expertise include consultation-liaison psychiatry, chronic pain management, psychosocial oncology, palliative care, and quality of life research.

10. Dr. Ajit K. Avasthi

Dr. Ajit K. Avasthi is a renowned psychiatrist and expert in the fields of schizophrenia, affective disorders, and psychosexual dysfunctions. He is currently affiliated with the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh. He also serves as a Consultant in Mental Health and Behavioural Sciences at Fortis Hospital, Mohali.

He has earned prestigious accolades over the years. These include the PPA-I Award in 2005, presented by the Indian Psychiatric Society for his Best Published Paper, followed by the same recognition in 2008 for another outstanding paper. Additionally, he received the Dr. Buckshey Award in 2011 during the XXXVIth North Zonal Conference of the Indian Psychiatric Society.

Dr. Avasthi’s primary areas of expertise encompass a range of mental health conditions, including schizophrenia, affective disorders such as depression and bipolar disorder, and psychosexual dysfunctions. His extensive knowledge and experience in these areas contribute to his reputation as a leading figure in the field of psychiatry.

He has been recognised as one of the top 2% scientists globally according to Stanford University’s 2025 list based on the composite score, excluding self-citations. He has an impressive rank of 71,272 in the list. 

11. Dr Gururaj Gopalkrishna

Dr. Gururaj Gopalkrishna, with an extensive background as a Senior Professor and Director at the National Institute of Mental Health and Neuro Sciences (NIMHANS), currently serves as an Advisor and Consultant in the fields of Public Health, Road Safety, and Mental Health.

In recognition of his exceptional contributions to the field, Dr. Gopalkrishna has been acknowledged in Stanford University’s 2% Scientists list for 2025. The data in the list shows that Dr. Gururaj Gopalkrishna Vaid holds a rank of 93,473 in the list based on the composite score excluding self-citations, and 92840 when all citations are included. By the end of 2024, Dr. Malhotra’s h-index, excluding self-citations, stands at 13, with a total of 1,169 citations for 2024 (excluding self-citations).

12. Dr. Vikas Menon

After pursuing his MBBS at JIPMER, Puducherry, Dr. Vikas Menon specialised further in psychiatry by completing his MD in Psychiatry from JIPMER and obtaining a DNB Psychiatry from the National Board of Examinations, New Delhi.

He is currently serving as a Professor of Psychiatry at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry.

Dr. Menon’s primary research interests revolve around mood disorders, suicide prevention, and digital psychiatry. He is particularly passionate about addressing the treatment gap in psychiatry, particularly through the use of innovative and frugal technologies that can make mental health care more accessible to underserved populations.

Dr. Menon has contributed significantly to academic literature, with 426 publications and over 132,000 reads and 7,026 citations to his name. His work is also recognized globally, earning him a spot in Stanford University’s 2% list of the world’s top scientists, with a ranking of 94,207. According to the list, by the end of 2024, his h-index, excluding self-citations, stands at 11.

13. Dr Telkar Srinivas Sathyanarayana Rao

Dr. Telkar Srinivas Sathyanarayana Rao currently works at the JSS Academy of Higher Education & Research in the Department of Psychiatry, where he serves as a prominent faculty member.

He has built a notable academic career after completing his B.Sc. from Sahyadri College.

His significant contributions to the field of psychiatry have earned him global recognition, and he has been ranked among the top 2% of scientists worldwide, according to Stanford University’s 2025 list, with a rank of 100,573.

His research interests encompass a broad range of topics, including oxidative stress, bipolar I disorder, hypomania, and the impact of mental disorders such as Alzheimer’s disease. He has also contributed to studies on the Coronavirinae family, COVID-19, the hippocampus, and the implications of social distancing.

14. Dr. Rakesh K. Chadda

Dr. Rakesh K. Chadda stands as one of India’s most distinguished psychiatrists, with over four decades of dedicated service to the field of mental health. He is currently serving as the Head of the Department of Psychiatry at Amrita Hospital.

Dr. Chadda has held several prominent positions across India’s most esteemed medical institutions. He served as Professor and Head of the Department of Psychiatry, as well as Chief of the National Drug Dependence Treatment Centre at the All India Institute of Medical Sciences (AIIMS), New Delhi. Earlier in his career, he contributed as Professor of Psychiatry at the Institute of Human Behaviour and Allied Sciences (IHBAS), Delhi, and also led the Department of Psychiatry at UCMS & GTB Hospital, Delhi.

On the international front, Dr. Chadda worked as a Consultant Psychiatrist in the National Health Service (NHS), United Kingdom, during 2004–05

He currently serves as President-Elect of the World Association of Social Psychiatry (WASP) for the 2022–25 term, having previously held the role of Secretary General (2019–22).

Dr. Chadda’s distinguished contributions to the field of psychiatry have been recognized globally through numerous prestigious honors and fellowships. He is a Fellow of the Royal College of Psychiatrists (UK) and a Distinguished International Fellow of the American Psychiatric Association, reflecting his international standing in mental health. He has also been named an Honorary Fellow of the World Association of Social Psychiatry (WASP) and an Honorary Member of the World Psychiatric Association (WPA)—testaments to his influence on global psychiatric practice and policy. In India, his achievements have been acknowledged with a Fellowship of the National Academy of Medical Sciences (NAMS).

His scholarly works have been published in prestigious journals like The British Journal of Psychiatry, American Journal of Psychiatry, The Lancet, Acta Psychiatrica Scandinavica, Psychiatric Research, and BJPsych International.

In recognition of his outstanding academic and research achievements, Dr. Chadda has been ranked among the top 2% of scientists globally, according to Stanford University’s 2025 list with 107,346 based on the composite score, excluding self-citations. By the end of 2024, Dr. Chadda’s h-index, excluding self-citations, stands at 8.

15. Dr. Shilpa Aggarwal

Dr. Shilpa Aggarwal, currently serving at SRCC Children’s Hospital, is a renowned Mental Health and Behavioural Sciences Specialist with over 10 years of clinical experience in the field of psychiatry. She holds extensive qualifications, including MBBS, MD in Medicine, DNB in Psychiatry from KEM Hospital, Mumbai, and advanced training in Child and Adolescent Psychiatry. She is also a Fellow of the Royal Australian and New Zealand College of Psychiatrists.

Her primary focus is evidence-based mental health care tailored to the unique needs of each patient. Dr. Aggarwal’s specialized knowledge in child and adolescent psychiatry allows her to effectively address a wide range of developmental, emotional, and behavioral challenges that affect younger populations.

She is a respected figure in the field, with 1,020 citations and an h-index of 16. Dr. Aggarwal’s inclusion in Stanford University’s list of the top 2% scientists worldwide for 2025. According to the data, it has achieved a rank of 107,667 based on the composite score, excluding self-citations. By the end of 2024, Dr. Shilpa Aggarwal’s h-index, excluding self-citations, stands at 8.

Powered by WPeMatico

Health Bulletin 04/October/2025

Here are the top health stories of the day:

Attacks on doctors threaten Lives and patient safety in Hospitals: Delhi HC Warns

While considering a criminal case against a patient’s attendant who had allegedly assaulted a doctor, the Delhi High Court bench took note of the compromise entered into between the parties and held that such an act of assault upon a medical professional, apart from endangering the lives of doctors and staff, also jeopardises the treatment of other patients needing urgent care.

“…this Court cannot lose sight of the fact that an act of assault upon a medical professional in a hospital not only endangers the life of doctors and staff, but also jeopardises the treatment of other patients in need of urgent care,” observed the High Court bench.

Even though the court quashed the criminal case against the accused (the patient’s attendant in question), it asked him to perform community service for a month.

For more details, check out the full story on the link mentioned below:

Assault upon medical professionals in hospitals endangers doctors’ lives, jeopardises patient care: Delhi HC

NMC Sets Deadline for Medical Colleges to submit NEET SS 2024 Admission details online

The Post Graduate Medical Education Board (PGMEB) has directed all medical colleges to submit information relating to admission made in Medical College/Postgraduate Institute through the National Eligibility and Entrance Test-Super Speciality (NEET SS) for the academic year 2024.

Through the letter, the Medical Colleges are required to ensure that all admissions in the SS courses are strictly in accordance with merit and are made transparently and fairly as envisaged in the Regulations. Any violation shall lead to the discharge of the concerned students from the courses and such action against the concerned Medical College/Institution as is permissible in law.

For more details, check out the full story on the link mentioned below:

NMC deadline to medical colleges to submit NEET SS 2024 admission details online


Punjab and Haryana HC criticises doctors over Illegible prescriptions

Slamming doctors for continuing to write illegible prescriptions despite access to computers, the Punjab and Haryana High Court has directed them to write in clear, bold capital letters until a comprehensive digital prescription system is established.

The court emphasised that patients have a fundamental right to receive clear and readable medical prescriptions, stressing that poor handwriting can directly impact a patient’s health and safety.

To prevent confusion, the court instructed the government to introduce handwriting training in medical curricula and to implement a nationwide digital system within two years. Until then, it directed doctors to write in bold, legible letters.

For more details, check out the full story on the link mentioned below:

Illegible Prescriptions Not Acceptable: Punjab and Haryana HC raps doctors


51 Lakh people in India are at risk of contracting Chikungunya in the Long Term: Study

India is projected to face the most significant long-term impact of chikungunya, with an estimated 51 lakh people at risk annually, according to a global modelling study published in BMJ Global Health. Brazil and Indonesia follow as the second and third most affected countries, with India and Brazil together accounting for 48% of the global healthcare and individual burden. Researchers from the London School of Hygiene and Tropical Medicine highlight chronic health effects as the major concern, with about half of those infected potentially suffering long-term disabilities.

Globally, over 1.4 crore people could be at risk yearly, predominantly children under 10 and adults over 80. Chikungunya is transmitted by Aedes mosquitoes, causing fever, severe joint pain, and in many cases, prolonged disability. With no specific treatments, two vaccines are approved in some countries, including the US. The study emphasises urgent public health preparedness and targeting vulnerable populations for vaccination to mitigate this growing threat.

REFERENCE: Kang H, Lim A, Auzenbergs M, Clark A, Colón-González FJ, Salje H, et al. Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study. BMJ Global Health. 2025;10:e018598. https://doi.org/10.1136/bmjgh-2024-018598

Powered by WPeMatico